You are here

Article Text

Article menu
Download PDFPDF
In perspective
Routine antibiotics in the febrile cancer patient: should immune checkpoint inhibitors affect our practice?

https://doi.org/10.1136/emermed-2020-210224

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Handling editor Gene Yong-Kwang Ong

    • Contributors KW and GR wrote the letter; KY, ZSSC and AL undertook a literature review on the topic.

    • Funding The Cabrini Research Institute has been funded by Roche, Bristol Myers Squibb, Merck & Co and AstraZenica for clinical trials investigating Immune checkpoint inhibitors.

    • Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; externally peer reviewed.